Back to top Open menu arrow
Download Reprints
Sections
MATERIALS AND METHODS RESULTS DISCUSSION CONCLUSIONS AND FUTURE DIRECTIONS Article Information Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Systematic Review PTSD and Trauma February 14, 2024

A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters

Justyne D. Rodas, MSc; Tony P. George, MD; Ahmed N. Hassan, MD

J Clin Psychiatry 2024;85(1):23r14862

ABSTRACT

Objective: Given the high rate of comorbid posttraumatic stress disorder (PTSD) and cannabis use, it is critical that further research be conducted to address the associated benefits and risks of cannabis use in this population. This systematic review evaluated evidence on the effects of cannabis and cannabinoids on PTSD symptoms and PTSD clusters.

Data Sources: A systematic search of PubMed, PsycINFO, and EMBASE databases was performed using terms related to cannabis, cannabinoids, and PTSD. Peer-reviewed studies available online in English and published from January 1990 through February 2023 were considered.

Study Selection: Included studies were experimental or observational in design, were conducted in cannabis-using patients with PTSD, used validated measures of PTSD, and were published in English.

Data Extraction: Extracted information included study aims, study design, sample size and sex, comparator group, cannabis-related characteristics, psychometric instruments, and relevant clinical findings regarding overall PTSD symptoms and cluster symptoms.

Results: Fourteen studies were included, 3 in a comorbid PTSD and cannabis use disorder (CUD) sample and 11 in a non-CUD sample. Of the 10 studies examining overall PTSD symptoms in a non-CUD sample, 5 suggested benefits associated with cannabis use and 5 suggested no effect or worsening of symptoms. Four studies reported benefits of cannabis for cluster B- and E-related symptoms in a non-CUD sample. All 3 studies in cannabis-using patients with a comorbid PTSD and CUD diagnosis reported risks for worsening of overall symptoms.

Conclusions: This review did not find major benefits of cannabinoids in improving overall PTSD symptoms. Some benefits with regard to cluster B and E symptoms were observed. Some risks with regard to worsening suicidal ideation and violent behavior were also reported. Individuals with a comorbid CUD diagnosis may be at greater risk for negative cannabis-related PTSD outcomes. More experimental studies are needed to determine the causal effects of cannabis and cannabinoids in PTSD.

J Clin Psychiatry 2024;85(1):23r14862

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. PubMed CrossRef
  2. Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260–2274. PubMed CrossRef
  3. Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137–1148. PubMed CrossRef
  4. Janoutová J, Janácková P, Serý O, et al. Epidemiology and risk factors of schizophrenia. Neuroendocrinol Lett. 2016;37(1):1–8. PubMed
  5. Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251–269. PubMed CrossRef
  6. Krysinska K, Lester D. Post-traumatic stress disorder and suicide risk: a systematic review. Arch Suicide Res. 2010;14(1):1–23. PubMed CrossRef
  7. Rapaport MH, Clary C, Fayyad R, et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6):1171–1178. PubMed CrossRef
  8. Pietrzak RH, Goldstein RB, Southwick SM, et al. Medical comorbidity of full and partial posttraumatic stress disorder in US adults: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2011;73(8):697–707. PubMed CrossRef
  9. McCauley JL, Killeen T, Gros DF, et al. Posttraumatic stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clin Psychol (New York). 2012;19(3):283–304. PubMed CrossRef
  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. Fifth Edition, Text Revision. American Psychiatric Association Publishing; 2022.
  11. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006;2006(1):CD002795. PubMed CrossRef
  12. Lewis C, Roberts NP, Gibson S, et al. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1709709. PubMed CrossRef
  13. Hill MN, Campolongo P, Yehuda R, et al. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018;43(1):80–102. PubMed CrossRef
  14. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 2012;204:207–229. PubMed CrossRef
  15. Ney LJ, Matthews A, Bruno R, et al. Cannabinoid interventions for PTSD: where to next? Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:124–140. PubMed CrossRef
  16. Ruehle S, Rey AA, Remmers F, et al. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol. 2012;26(1):23–39. PubMed CrossRef
  17. Ganon-Elazar E, Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J Neurosci. 2009;29(36):11078–11088. PubMed CrossRef
  18. Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress
. Dialogues Clin Neurosci. 2020;22(3):229–239. PubMed CrossRef
  19. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534. PubMed CrossRef
  20. Niyuhire F, Varvel SA, Martin BR, et al. Exposure to marijuana smoke impairs memory retrieval in mice. J Pharmacol Exp Ther. 2007;322(3):1067–1075. PubMed CrossRef
  21. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836. PubMed CrossRef
  22. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034–1040. PubMed CrossRef
  23. Lake S, Kerr T, Buxton J, et al. Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? evidence from a population-based cross-sectional study of Canadians. J Psychopharmacol. 2020;34(2):181–188. PubMed CrossRef
  24. Bilevicius E, Sommer JL, Asmundson GJG, et al. Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: results from an American nationally representative study. Depress Anxiety. 2019;36(11):1036–1046. PubMed CrossRef
  25. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  26. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. PubMed CrossRef
  27. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. PubMed CrossRef
  28. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. 2013. https://web.archive.org/web/20210716121605id_/http://www3.med.unipmn.it/dispense_ebm/2009-2010/Corso%20Perfezionamento%20EBM_Faggiano/NOS_oxford.pdf
  29. Vardell E, Malloy M. Joanna Briggs Institute: an evidence-based practice database. Med Ref Serv Q. 2013;32(4):434–442. PubMed CrossRef
  30. Bonn-Miller MO, Brunstetter M, Simonian A, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 2022;7(2):214–223. PubMed CrossRef
  31. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–564. PubMed CrossRef
  32. Elms L, Shannon S, Hughes S, et al. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25(4):392–397. PubMed CrossRef
  33. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46(1):73–77. PubMed CrossRef
  34. Pillai M, Erridge S, Bapir L, et al. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. Expert Rev Neurother. 2022;22(11-12):1009–1018. PubMed CrossRef
  35. Allan NP, Ashrafioun L, Kolnogorova K, et al. Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: Increased risk from marijuana use. Depress Anxiety. 2019;36(11):1072–1079. PubMed CrossRef
  36. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174–1180. PubMed CrossRef
  37. Johnson MJ, Pierce JD, Mavandadi S, et al. Mental health symptom severity in cannabis using and non-using veterans with probable PTSD. J Affect Disord. 2016;190:439–442. PubMed CrossRef
  38. Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34(8):587–591. PubMed CrossRef
  39. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One. 2021;16(3):e0246990. PubMed CrossRef
  40. Bonn-Miller MO, Boden MT, Vujanovic AA, et al. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychol Trauma. 2013;5(2):193–200. CrossRef
  41. Livingston NA, Farmer SL, Mahoney CT, et al. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2022;36(2):131–143. PubMed CrossRef
  42. Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: impact of specific substances and achievement of abstinence. Drug Alcohol Depend. 2015;156:70–77. PubMed CrossRef
  43. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588. PubMed CrossRef
  44. Botsford SL, Yang S, George TP. Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict. 2020;29(1):9–26. PubMed CrossRef
  45. Rehman Y, Saini A, Huang S, et al. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. 2021;8(3):414–434. PubMed CrossRef
  46. Wilkinson ST, Radhakrishnan R, D’Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016;77(8):1050–1064. PubMed CrossRef
  47. Steenkamp MM, Blessing EM, Galatzer-Levy IR, et al. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207–216. PubMed CrossRef
  48. LaFrance EM, Glodosky NC, Bonn-Miller M, et al. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298–304. PubMed CrossRef
  49. Feinberg I, Jones R, Walker JM, et al. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17(4):458–466. PubMed CrossRef
  50. Feinberg I, Jones R, Walker J, et al. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther. 1976;19(6):782–794. PubMed CrossRef
  51. Schierenbeck T, Riemann D, Berger M, et al. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–389. PubMed CrossRef
  52. Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep. 2008;31(6):901–908. PubMed CrossRef
  53. Ross RJ, Ball WA, Dinges DF, et al. Rapid eye movement sleep disturbance in posttraumatic stress disorder. Biol Psychiatry. 1994;35(3):195–202. PubMed CrossRef
  54. Singareddy RK, Balon R. Sleep in posttraumatic stress disorder. Ann Clin Psychiatry. 2002;14(3):183–190. PubMed CrossRef
  55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Includes ICD-9-CM Codes Effective October 1, 1996. Fourth Edition. 1998.
  56. Weathers FW, Bovin MJ, Lee DJ, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383–395. PubMed CrossRef
  57. Gradus JL, Qin P, Lincoln AK, et al. Posttraumatic stress disorder and completed suicide. Am J Epidemiol. 2010;171(6):721–727. PubMed CrossRef
  58. Sher L. Neurobiology of suicidal behavior in post-traumatic stress disorder. Expert Rev Neurother. 2010;10(8):1233–1235. PubMed CrossRef
  59. Vinod KY. Role of the endocannabinoid system in the neurobiology of suicide. In: Dwivedi Y, ed. The Neurobiological Basis of Suicide. CRC Press/Taylor & Francis; 2012.
  60. Hungund BL, Vinod KY, Kassir SA, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9(2):184–190. PubMed CrossRef
  61. Pava MJ, den Hartog CR, Blanco-Centurion C, et al. Endocannabinoid modulation of cortical up-states and NREM sleep. PLoS One. 2014;9(2):e88672. PubMed CrossRef
  62. Pava MJ, Makriyannis A, Lovinger DM. Endocannabinoid signaling regulates sleep stability. PLoS One. 2016;11(3):e0152473. PubMed CrossRef
  63. Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013;27(3):312–316. PubMed CrossRef
  64. Hsiao YT, Yi PL, Li CL, et al. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012;62(1):373–384. PubMed CrossRef
  65. Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci. 2018;12:502. PubMed CrossRef
  66. Carabellese F, Candelli C, Martinelli D, et al. Cannabis use and violent behaviour: a psychiatric patients cohort study in southern Italy. Riv Psichiatr. 2013;48(1):43–50. PubMed
  67. Norström T, Rossow I. Cannabis use and violence: is there a link? Scand J Public Health. 2014;42(4):358–363. PubMed CrossRef
  68. Sorkhou M, Johnstone S, Kivlichan AE, et al. Does cannabis use predict aggressive or violent behavior in psychiatric populations? a systematic review. Am J Drug Alcohol Abuse. 2022;48(6):631–643. PubMed CrossRef
  69. Dellazizzo L, Potvin S, Dou BY, et al. Association between the use of cannabis and physical violence in youths: a meta-analytical investigation. Am J Psychiatry. 2020;177(7):619–626. PubMed CrossRef
  70. Bayrakçı A, Sert E, Zorlu N, et al. Facial emotion recognition deficits in abstinent cannabis dependent patients. Compr Psychiatry. 2015;58:160–164. PubMed CrossRef
  71. Castro-Vale I, Severo M, Carvalho D. Lifetime PTSD is associated with impaired emotion recognition in veterans and their offspring. Psychiatry Res. 2020;284:112666. PubMed CrossRef
  72. Zimmermann K, Walz C, Derckx RT, et al. Emotion regulation deficits in regular marijuana users. Hum Brain Mapp. 2017;38(8):4270–4279. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe